We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

MRKR Marker Therapeutics Inc

-0.08 (-1.62%)
Sep 25 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 43,464
Bid Price 4.81
Ask Price 4.97
News -
Day High 5.09


52 Week Range


Day Low 4.66
Company Name Stock Ticker Symbol Market Type
Marker Therapeutics Inc MRKR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -1.62% 4.85 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.80 4.66 5.09 4.81 4.93
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
441 43,464 $ 4.77 $ 207,290 - 0.6706 - 9.6799
Last Trade Time Type Quantity Stock Price Currency
19:55:34 10 $ 4.85 USD

Marker Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
42.72M 8.81M - 9.01M -29.93M -3.40 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Marker Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MRKR Message Board. Create One! See More Posts on MRKR Message Board See More Message Board Posts

Historical MRKR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.295.554.665.1223,050-0.44-8.32%
1 Month5.586.79994.665.7063,180-0.73-13.08%
3 Months3.069.67993.066.19136,9281.7958.5%
6 Months0.82859.67990.67062.38507,3994.02485.4%
1 Year3.349.67990.67062.69366,3131.5145.21%
3 Years15.3037.700.670615.30885,788-10.45-68.3%
5 Years100.10102.500.670621.45680,933-95.25-95.15%

Marker Therapeutics Description

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Your Recent History
Marker The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com

V: D: 20230926 03:49:34